Please assess the completion status of the following clinical trial:

Trial Title: A Study Investigating the Renal Tolerability, Efficacy, and Safety of a CNI-free Versus a Standard Regimen in de Novo Heart Transplant (HTx) Recipients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Heart transplantation, 3 months prior to enrollment~* Patients have to receive an immunosuppressive regimen with Sandimmun® Optoral, Certican® and corticosteroids~* Sufficient graft function~* Sufficient renal function~* Females capable of becoming pregnant must have a negative serum pregnancy test within 7 days prior to or at baseline, and are required to practice an approved method of birth control for the duration of the study and for a period of 6 weeks following discontinuation of study medication, even where there has been a history of infertility~Exclusion criteria:~* Multi-organ recipients, re-transplantation, or previous transplant with any other organ.~* Patients who are recipients of A-B-O incompatible transplants~* Cold ischemia time \>6 hours~* Historical or current peak PRA of \> 25% at time of transplantation~* Already existing antibodies against the HLA-type of the receiving transplant Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- CNI-regimen (Type: ACTIVE_COMPARATOR): CNI-regimen: cyclosporine A (CyA) or tacrolimus (TAC) with everolimus (EVR) with corticosteroids
- CNI-free-regimen (Type: EXPERIMENTAL): CNI-free regimen: everolimus (EVR) with MPA (either MMF or enteric coated mycophenolate sodium (EC-MPS)) and corticosteroids

Based on this trial design, predict the completion outcome and termination type (if applicable).